Skip to main content

Search Results

MLB All-Star Player Designs Caps to Benefit LLS

The Leukemia & Lymphoma Society (LLS) hit a homerun when the Washington Nationals outfielder, Bryce Harper announced LLS will be a beneficiary of his limited edition, custom-designed baseball caps.   Known for extraordinary talents in the outfield, Bryce’s talent as a hat designer is now getting recognition: He helped design the New Era caps which went on sale Wednesday, August 24.

Ibritumomab tiuxetan

Ibritumomab tiuxetan is FDA approved to treat people who have relapsed or refractory, low-grade or follicular non-Hodgkin lymphoma (NHL), including patients with follicular NHL that did not respond to therapy with rituximab. It is also FDA approved to treat patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy. This drug is a monoclonal antibody with an attached radioisotope to deliver radiation therapy to the lymphoma cells.

Hawks Legend Surprises Young Fan & Survivor

At 23 years old, Alex Hawkins just started a new job, had a great boyfriend and was an active runner. She spent her free time watching Atlanta Hawks games – she was a fan since she could talk – and enjoying time with her family, chasing around her two nephews while in the midst of helping her sister prepare for a new baby.

After finding an abnormal lump on her neck in 2014, she was diagnosed with B-Cell Non-Hodgkin lymphoma, stage III.

Leukemia survivor and Honored Hero, Jelien, smiling with a Subaru blanket

Beyond Blankets: Subaru Loves to Care brings comfort and warmth

Blood cancer treatment can be a scary and confusing time. And blood cancer patients want to feel like they’re not alone. 

That’s why The Leukemia & Lymphoma Society (LLS) and Subaru are partnering to bring warmth and comfort to blood cancer patients through warm blankets, patient care kits, and handwritten notes of encouragement.

Targeting AML

 

Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease.

RBG

Statement on the Death of Supreme Court Justice and Trailblazer Ruth Bader Ginsburg

Photo by Nikki Khan/The Washington Post via Getty Images

 

Here at The Leukemia & Lymphoma Society (LLS), we are devastated to learn of the passing of Associate Justice Ruth Bader Ginsburg from complications of metastatic pancreatic cancer. As the global leader in the fight against blood cancer, we stand with the cancer community – and all Americans – in mourning this trailblazer whose contributions to public health and equality will be felt by generations to come.

Meet an LLS Advocacy Volunteer: Amanda Steffy

Amanda Steffy of Pasadena, Calif. is one of The Leukemia & Lymphoma Society’s most passionate policy advocates. She frequently travels to Washington, D.C. to speak with lawmakers about the importance of high-quality, affordable healthcare for cancer patients. In California, where she works as an instrument systems engineer for NASA JPL, she recruits and teaches others to do the same.

This May, Steffy joins LLS for its first-ever virtual advocacy event. In this interview, Steffy explains how she first became involved in advocacy and why she’s so passionate about the work.

Leveraging cancer registries, clinical trials, and community partnerships to address disparities in pediatric, adolescent, and young adult lymphoma

I aim to identify drivers of pediatric and adolescent/young adult lymphoma disparities so that targeted health equity interventions can be developed. Integration of large datasets, systematic collection of social determinants data in clinical trials, and collaboration with patient advocates will: a) create new population-based resources to study lymphoma outcomes; b) establish a novel framework for equity research in lymphoma clinical trials; and c) identify real-world targets for intervention.

Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma

Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.